0 seconds of 1 minute, 49 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
01:49
01:49
 
  • Mednow (MNOW) reported Q1/23 revenue increased approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year
  • Mednow patient count by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22
  • Reduced costs by 30 per cent, achieved additional cost savings post-Q1’23 to further reduce cash burn
  • Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results
  • Mednow is a healthcare technology company
  • Mednow Inc. (MNOW) opened trading at $0.29 per share

Mednow (MNOW) has released its financial results for the period ending October 31, 2022 (Q1 2023).

In fiscal Q1, revenue increased by approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year

Mednow’s patient count increased by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22.

Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results.

Mednow is a Canadian-based healthcare technology company. Mednow.ca provides virtual pharmacy and telemedicine services, as well as doctor home visits.

Mednow Inc. (MNOW) opened trading at $0.29 per share. 


More From The Market Online
NurExone Biologic Inc

A promising investment in regenerative medicine

Biopharmaceutical company NurExone (TSXV:NRX) reached a significant milestone in its efforts to revolutionize spinal cord injury treatments.
Hypha Labs promo

The rise of functional mushrooms and the future of micropearls

Rising demand offers an enticing incentive for companies to more efficiently deliver functional mushrooms' benefits to consumers.
Medicine factory line

Buyout disclosure sends Theratechnologies stock soaring

Future Pak discloses its intention to acquire Theratechnologies (TSX:TH), a biopharmaceutical company focused on oncology and HIV.
Cancer therapy targeting malignant cell

Small-cap cancer therapy innovator raises $20M in flexible funding

Oncolytics Biotech (TSX:ONC), a cancer therapy developer, announces a US$20M financing with institutional investor Alumni Capital.